PGEN
PRECIGEN, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 13 ▲ Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M…
- May 28 ▼ 5 insiders sell $1.1M at $4.36
- Jun 29 to Jul 1 ▼ 2 days of insider sells: $3.4M by 3 insiders, avg $5.78
- Jul 31 to Aug 6 ▼ 3 days of insider sells: $1.1M by 2 insiders, avg $6.31
- Aug 21 to Aug 26 ▼ 3 days of insider sells: $2.3M by 3 insiders, avg $7.46
- Aug 21 ▲ 1 insider buy $24.7K at $7.23
- Sep 25 B. Riley Securities initiates
- Nov 5 ▲ Precigen reported Q3 2026 revenue of $74.1M (vs. $71.6M consensus) a…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $24.7K at an average $7.23. 6 insiders sold $8.0M. Price is 41% below their cost.
- InstitutionsBULLISH
Q3 2026: 32 added (1 new), 14 trimmed or exited. Largest new: Qube Research & Technologies $18.9M.
- AnalystsBULLISH
8 of 10 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate $0.110 → $0.114 over 90 days. 2 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −3.2% to 44.91M shares. 8.6 days to cover, ≈12.5% of shares.
- TrendDOWNTREND
36% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 4.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $33.5M |
| FIRST TRUST ADVISORS LP | ADD | $22.5M |
| Nuveen, LLC | DOUBLED | $20.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $20.0M |
| Qube Research & Technologies Ltd | NEW | $18.9M |
| UBS Group AG | DOUBLED | $13.5M |
| BARCLAYS PLC | ADD | $11.6M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | $5.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is below the lowest target. Median implies +179%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only REITERATE | |
| Nov 5, 2026 | Citizens MAINTAIN | Market Outperform |
| Sep 25, 2026 | B. Riley Securities INITIATE | Buy |
| Aug 5, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 3, 2026 | HC Wainwright & Co. REITERATE | Buy |
| May 28, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Thomasian Harry Jr. Chief Financial Officer Sep 23, 2026 | EXERCISE | $100.0K |
Thomasian Harry Jr. Chief Financial Officer Sep 23, 2026 | EXERCISE | $1.92 |
Thomasian Harry Jr. Chief Financial Officer Sep 23, 2026 | EXERCISE | $50.7K |
Thomasian Harry Jr. Chief Financial Officer Sep 23, 2026 | EXERCISE | $1.21 |
KINDLER JEFFREY B Director Aug 26, 2026 | SELL | $1.4M |
Tennant Phil Chief Commercial Officer Aug 25, 2026 | EXERCISE | $127.5K |
Shah Rutul R Chief Operating Officer Aug 25, 2026 | SELL | $115.1K |
Shah Rutul R Chief Operating Officer Aug 25, 2026 | EXERCISE | $35.7K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.11 | $0.10–$0.13 | +3.4% | $87.9M |
| Next Q | $0.14 | $0.11–$0.17 | -19.6% | $92.6M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $0.62 | $0.43–$0.95 | -1.5% | $442.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 2 bullish · 2 bearish · 9 neutral- BULLISH 8-KNov 4, 2026
Precigen reported Q3 2026 revenue of $74.1M (vs. $71.6M consensus) and GAAP diluted EPS of $0.08…
PAPZIMEOS revenue growth trajectory and positive cash flow achievement are the key metrics to track. Monitor the pace of patient hub enrollment and conversion to treated patients, as well as the EMA…
- NEUTRAL CLUSTERAug 28, 2026
A mixed insider cluster at Precigen shows a director selling $1.38M in open-market shares and the…
The cluster is dominated by liquidity-driven sales (option exercises + tax withholding) from C-suite executives, with a single director's $1.38M open-market sale being the only notable cash…
- NEUTRAL 144Aug 26, 2026
Director Jeffrey Kindler filed a Form 144 to sell 185,000 shares of Precigen (PGEN) at an…
This is a routine diversification sale by a director, not a CEO/CFO, and the dollar amount is small relative to market cap. The strong institutional accumulation and bullish analyst consensus…
- BEARISH CLUSTERAug 25, 2026
Precigen insiders show a mixed cluster: Director Nancy Agee made a small $25K open-market buy…
The COO's $260K open-market sale at $7.50 is a notable bearish signal from a C-suite insider, especially given no apparent 10b5-1 plan. The director's $25K buy is too small to offset. Monitor for…
All PGEN filing & press-release reports (13)
- 8-K reportNov 4, 2026
- CLUSTER reportAug 28, 2026
- 144 reportAug 26, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportJul 1, 2026
- 8-K reportJun 24, 2026
- CLUSTER reportJun 1, 2026
- CLUSTER reportJun 1, 2026
- 8-K reportMay 13, 2026
- 144 reportMar 30, 2026